RxDoctor Payments DataLook up a doctor →

Erin Dwyer

Family · San Diego, CANPI 1003260894

Payments from drug & device makers

$189,015in general payments, 2019–2025

Across 918 payments — averaging $205.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$161K
  • Axonics, Inc.$7K
  • Boston Scientific$5K
  • SRS Medical Systems, Inc.$4K
  • Johnson & Johnson$3K
  • Urogen Pharma, Inc.$1K
  • plus $9K from 48 others

What the payments were for

  • Consulting fees$21,97412%
  • Speaking & faculty fees$114,68661%
  • Travel & lodging$20,03911%
  • Food & beverage$32,00817%
  • Education$3070%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$189,015 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$76,668
Medicare patients
203
Services billed
4,042

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron101$79,108
MyrbetriqMirabegron82$48,092
PremarinEstrogens, Conjugated19$7,921
Estradiol118$7,255
Solifenacin Succinate102$2,410
Tamsulosin Hcl146$1,418
Tolterodine Tartrate ErTolterodine Tartrate19$946
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst31$207
Doxazosin Mesylate28$187
Doxycycline Monohydrate22$162
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim33$138
Finasteride24$109
Ciprofloxacin Hcl23$52
Doxycycline Hyclate11$42
Ibuprofen11$21

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$290$79,108101 claims
Astellas Pharma US IncMyrbetriq$752$48,09282 claims
PfizerPremarin$474$7,92119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.

Other family in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →